Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesNeurology/NeurosurgerySierra Health and Life FcRn blockers Coverage Upda…
    Ask Trek AI about this page
    Modifiedsierra health and lifePolicy 2026D0111N

    FcRn blockers (Rystiggo, Vyvgart, Vyvgart Hytrulo) coverage for gMG and CIDP

    Customize your policy alerts

    Sign up for sierra health and life Policy 2026D0111N alerts

    Get alerted when Policy 2026D0111N changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity criteria and prior authorization requirements for provider‑administered FcRn blocker therapies (rozanolixizumab, efgartigimod products) for generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP) under Sierra Health and Life medical benefit.

    Policy Summary
    Payersierra health and life
    PolicyFcRn blockers (Rystiggo, Vyvgart, Vyvgart Hytrulo) coverage for gMG and CIDP
    Policy CodePolicy 2026D0111N
    Change TypeHCPCS code list updated
    Effective DateJan 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with medical records confirming antibody status, MGFA class, MG‑ADL score, and prior therapy history.
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    Added HCPCS code J9256 and removed C9305 from the applicable codes list.

    3drug products addressed
    ≥5MG-ADL minimum
    12 monthsauth period (max)
    50–63 daysmin interval
    J9332,J9333,J9334,J9256HCPCS codes listed
    67.7%MG-ADL responder rate

    Coverage Criteria for FcRn Blocker Therapies

    Rystiggo — Initial Therapy

    Rystiggo (rozanolixizumab‑noli) for generalized myasthenia gravis (AChR+ or MuSK+): Covered when ALL of the following are met

    Rystiggo initiation criteria: Patient has diagnosis of generalized myasthenia gravis (gMG); patient has not failed a previous course of Rystiggo; positive serologic test for anti‑AChR antibodies OR positive serologic test for anti‑MuSK antibodies; MGFA Clinical Classification class II, III, or IV at initiation; MG‑ADL total score >= 5 at initiation; prescribed by, or in consultation with, a neurologist; Rystiggo is dosed according to the US FDA labeled dosing for gMG; patient is not receiving Rystiggo in combination with a complement inhibitor, another FcRn blocker, or an immune globulin; Rystiggo will be given no sooner than 63 days from the start of the previous treatment cycle; initial authorization will be for no more than 12 monthsMG-ADL >= 5

    For AChR‑positive patients: history of failure of >=2 immunosuppressive agents over >=12 months OR failure of >=1 immunosuppressive therapy plus >=4 courses of plasmapheresis and/or IVIG over >=12 months; for MuSK‑positive patients: history of failure of >=1 immunosuppressive agent over >=12 months

    Rystiggo — Continuation Therapy

    Rystiggo — Continuation of Therapy: Covered when ALL of the following are met

    Rystiggo continuation criteria: Patient has previously been treated with Rystiggo; documentation (chart notes, lab tests) demonstrates improvement and/or maintenance of at least a 2‑point improvement in MG‑ADL score from pre‑treatment baseline AND reduction in signs and symptoms of myasthenia gravis; maintenance, reduction, or discontinuation of baseline immunosuppressive therapy (add‑on, dose escalation, or additional rescue therapy from baseline is considered treatment failure); patient is not receiving Rystiggo in combination with a complement inhibitor, another FcRn blocker, or an immune globulin; Rystiggo is not given sooner than 63 days from the start of the previous treatment cycle; Rystiggo is dosed according to the US FDA labeled dosing for gMG; prescribed by, or in consultation with, a neurologist; reauthorization will be for no more than 12 months

    Improvement is defined as >=2 point reduction in MG‑ADL from pretreatment baseline

    Vyvgart / Vyvgart Hytrulo — Initial Therapy (gMG)

    Vyvgart and Vyvgart Hytrulo for AChR‑positive generalized myasthenia gravis: Covered when ALL of the following are met

    Vyvgart initial criteria: Patient has diagnosis of generalized myasthenia gravis (gMG); patient has not failed a previous course of Vyvgart or Vyvgart Hytrulo; positive serologic test for anti‑AChR antibodies; MGFA Clinical Classification class II, III, or IV at initiation; MG‑ADL total score >= 5 at initiation; prescribed by, or in consultation with, a neurologist; Vyvgart or Vyvgart Hytrulo is dosed according to the US FDA labeled dosing for gMG; patient is not receiving Vyvgart or Vyvgart Hytrulo in combination with a complement inhibitor, another FcRn blocker, or an immune globulin; therapy will be given no sooner than 50 days from the start of the previous treatment cycle; initial authorization will be for no more than 12 months; AND one of the following prior‑therapy requirements: history of failure of at least two immunosuppressive agents over >=12 months OR history of failure of at least one immunosuppressive therapy plus four or more courses of plasmapheresis and/or IVIG over >=12 monthsMG-ADL >= 5

    Vyvgart / Vyvgart Hytrulo — Continuation Therapy (gMG)

    Vyvgart and Vyvgart Hytrulo — Continuation of Therapy (gMG): Covered when ALL of the following are met

    Vyvgart continuation criteria: Patient has previously been treated with Vyvgart or Vyvgart Hytrulo; documentation (chart notes, lab tests) demonstrates improvement and/or maintenance of at least a 2‑point improvement in MG‑ADL score from pre‑treatment baseline AND reduction in signs and symptoms of myasthenia gravis; maintenance, reduction, or discontinuation of baseline immunosuppressive therapy (add‑on, dose escalation, or additional rescue therapy from baseline is considered treatment failure); patient is not receiving Vyvgart or Vyvgart Hytrulo in combination with a complement inhibitor, another FcRn blocker, or an immune globulin; therapy is not given sooner than 50 days from the start of the previous treatment cycle; Vyvgart or Vyvgart Hytrulo is dosed according to the US FDA labeled dosing for gMG; prescribed by, or in consultation with, a neurologist; reauthorization will be for no more than 12 months

    Improvement is defined as >=2 point reduction in MG‑ADL from pretreatment baseline

    Vyvgart Hytrulo — Initial Therapy (CIDP)

    Vyvgart Hytrulo for chronic inflammatory demyelinating polyneuropathy (CIDP): Covered when ALL of the following are met

    Vyvgart Hytrulo CIDP initial criteria: Patient has not failed a previous course of Vyvgart Hytrulo; diagnosis of CIDP confirmed by: progressive symptoms for at least 2 months; symptomatic polyradiculoneuropathy with progressive or relapsing motor or sensory impairment of more than one limb; electrodiagnostic findings consistent with EFNS/PNS criteria for definite CIDP demonstrating at least one of the listed nerve conduction abnormalities; trial and failure (>=2 months), contraindication, or intolerance to corticosteroids; AND either trial and failure (>=3 months) of IVIG/SCIG OR intolerance to all IVIG/SCIG with dose optimized OR contraindication to all IVIG/SCIG; patient is not receiving Vyvgart Hytrulo in combination with an immune globulin; Vyvgart Hytrulo is dosed according to the US FDA labeled dosing for CIDP; prescribed by, or in consultation with, a neurologist; initial authorization will be for no more than 12 months

    Electrodiagnostic criteria include motor distal latency prolongation in 2 nerves; reduction of motor conduction velocity in 2 nerves; prolonged F‑wave latency in 2 nerves; absence of F‑waves in >=1 nerve; partial motor conduction block in >=1 nerve; abnormal temporal dispersion in >=2 nerves; or distal CMAP duration increase in >=1 nerve

    Vyvgart Hytrulo — Continuation Therapy (CIDP)

    Vyvgart Hytrulo — Continuation of Therapy (CIDP): Covered when ALL of the following are met

    Vyvgart Hytrulo CIDP continuation criteria: Patient has previously been treated with Vyvgart Hytrulo; documentation of positive clinical response to therapy as measured by an objective scale (e.g., Rankin, Modified Rankin, MRC); patient is not receiving Vyvgart Hytrulo in combination with an immune globulin; Vyvgart Hytrulo is dosed according to the US FDA labeled dosing for CIDP; prescribed by, or in consultation with, a neurologist; reauthorization will be for no more than 12 months

    Covered indications and supporting clinical criteria

    Covered when clinical evidence and indication align with trial populations and FDA indications

    gMG AChR-positive indication

    • Baseline clinical severity: Baseline MG‑ADL score consistent with trial enrollment (e.g., ≥5 used in efgartigimod IV trials; rozanolixizumab trials enrolled patients with MG‑ADL ≥3 with ≥3 non‑ocular points) and MGFA class II‑IV

      Reflects trial inclusion criteria

    • Stable concomitant therapy: On stable dose of MG therapies (AChE inhibitors, steroids, or non‑steroidal immunosuppressive therapies) prior to treatment

      Reflects trial requirement

    • Serum IgG requirement: Serum IgG at or above trial‑specified minimum (e.g., ≥6 g/L for efgartigimod IV; ≥5.5 g/L for rozanolixizumab)

      Safety enrollment criterion

    The policy explicitly prohibits concurrent administration of these FcRn‑targeting agents with certain other immunomodulatory therapies. Concomitant use with a complement inhibitor (e.g., eculizumab, ravulizumab, zilucoplan), another FcRn blocker (e.g., Vyvgart, Vyvgart Hytrulo when the requested product is Rystiggo or vice versa), or immune globulin (IVIG/SCIG) is not permitted and will render the combination non‑covered under this policy. This restriction applies to both initiation and continuation authorizations and mirrors the language used for Rystiggo and Vyvgart/Vyvgart Hytrulo in the criteria sets.

    When documenting therapy plans, providers must confirm the patient is not receiving any of the excluded concomitant agents and that the requested FcRn blocker will be dosed per FDA labeling and at the minimum interval from the prior treatment cycle specified for the product (e.g., no sooner than 63 days for Rystiggo; no sooner than 50 days for Vyvgart/Vyvgart Hytrulo).

    Information about FDA approval is provided for context only. FDA approval alone is not a basis for coverage; coverage determinations are made using the clinical criteria and prior authorization requirements specified in this policy.

    If the patient does not meet the required initiation criteria (for example, lacks the required antibody positivity, does not meet the MG‑ADL minimum, or lacks diagnostic confirmation for CIDP), the request should be managed as not medically necessary. Providers should submit complete medical records documenting diagnosis, serologic testing, baseline clinical scores, prior therapy trials, or reasons why specified prior therapies were contraindicated or not tolerated to support reconsideration.

    Where appropriate, consider alternative evidence‑based therapies that meet the patient’s diagnostic and prior‑therapy profile (e.g., standard immunosuppressive agents, IVIG, or plasmapheresis for gMG or CIDP), and document rationale for the selected therapeutic approach and any contraindications to the preferred options.

    Medicare currently has no National Coverage Determination (NCD) or local LCD/LCA addressing Vyvgart, Vyvgart Hytrulo, or Rystiggo. In the absence of an applicable Medicare NCD/LCD, coverage for these agents depends on the payer’s specific policy and the member’s plan benefits; therefore, lack of a local Medicare coverage article could result in non‑coverage for some members if the payer’s medical policy is not met.

    Note that general Medicare billing rules still apply for Part B outpatient drugs furnished incident to a physician’s service; however, preferred therapy criteria described in this policy are not applicable to Medicare Advantage members per CMS guidance.

    Billing and Coding

    Applicable HCPCS / J-codesHCPCS
    J9256Injection, nipocalimab-aahu, 3 mg
    J9332Injection, efgartigimod alfa-fcab, 2 mg
    J9333Injection, rozanolixizumab-noli, 1 mg
    J9334Injection, efgartigimod alfa, 2 mg and hyaluronidase-qvfc
    Applicable ICD-10 CodesICD-10
    G61.81Chronic inflammatory demyelinating polyneuritis
    G70.00Myasthenia gravis without (acute) exacerbation
    G70.01Myasthenia gravis with (acute) exacerbation
    Applicable HCPCS code editsHCPCS
    J9256added HCPCS code (as listed in policy)
    C9305removed HCPCS code (was previously listed)
    MG-ADL minimum for initiation
    MG-ADL minimum at initiationMG‑ADL total score ≥ 5 required at therapy start
    ApplicabilityRequired for initiation of Rystiggo and Vyvgart products per policy initiation criteria
    Source contextSpecified in instructions for use and criteria sets for initiation
    Clinical score responder thresholds
    MG-ADL responder definition≥2‑point reduction in total MG‑ADL from treatment‑cycle baseline sustained for ≥4 consecutive weeks
    QMG responder definition≥3‑point reduction in total QMG score from treatment‑cycle baseline sustained for ≥4 consecutive weeks

    Provider Actions, Prior Authorization, and Documentation

    Prior Authorization

    Prior authorization: submit full medical records showing all initiation criteria

    Submit a prior authorization request with complete medical records demonstrating the patient meets the initiation criteria for the requested FcRn blocker (antibody status, MGFA class II–IV, MG‑ADL baseline score, prior therapy history) and that the patient has not previously failed the same agent.

    • Include chart notes and laboratory values showing diagnosis of gMG or CIDP as applicable.
    • Confirm patient has not failed a previous course of the requested agent (Rystiggo, Vyvgart, or Vyvgart Hytrulo).
    • For gMG, document positive serologic testing (anti‑AChR or anti‑MuSK per agent) and MGFA class II–IV.
    • Provide MG‑ADL total score at initiation (see thresholds).

    Background and Mechanism

    Efgartigimod (including the coformulation with hyaluronidase) and rozanolixizumab are biologic agents that target the neonatal Fc receptor (FcRn) to reduce circulating IgG, including pathogenic autoantibodies such as anti‑AChR. Efgartigimod alfa acts as an FcRn blocker and has been studied both as an IV formulation and as a subcutaneous formulation coformulated with hyaluronidase to facilitate SC administration; hyaluronidase transiently increases subcutaneous tissue permeability to allow larger‑volume SC dosing.

    Rozanolixizumab is likewise an FcRn‑targeting monoclonal agent developed for subcutaneous administration in generalized myasthenia gravis. Clinical trials for these agents used disease‑specific outcome scales (e.g., MG‑ADL and QMG) and defined responder thresholds that underpin the policy’s initiation and continuation criteria.

    Definitions and Responder Criteria

    MG‑ADL responder — definition reference
    MG-ADL responder (policy definition)Patient with a ≥2‑point reduction in total MG‑ADL score compared to the treatment‑cycle baseline for at least 4 consecutive weeks
    MG-ADL scale rangeMG‑ADL total score ranges 0–24; higher scores indicate greater impairment
    Clinical relevance2‑point change balances sensitivity and specificity for clinically meaningful improvement per validation analyses
    FcRn blocker — class mechanism
    Mechanism of actionFcRn blockers bind the neonatal Fc receptor (FcRn) resulting in reduction of circulating IgG, including pathogenic autoantibodies
    Drug examples in policyEfgartigimod alfa‑fcab, efgartigimod alfa with hyaluronidase, and rozanolixizumab bind FcRn to lower serum IgG

    Revision History and Policy Changes

    2026-01-01material_changeLatest

    Updated applicable HCPCS codes: added J9256 and removed C9305; previous policy version archived.

    Policy number: 2026D0111N. Effective date: 2026-01-01. Scope: Defines medical necessity criteria and prior authorization requirements for provider‑administered FcRn blocker therapies (Rystiggo, Vyvgart, Vyvgart Hytrulo) for generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP) under the Sierra Health and Life medical benefit.

    Change status: This policy is modified with an operational coding update — the applicable HCPCS code list was revised effective 01/01/2026 (an HCPCS code was added and a previously listed code removed). Initial and reauthorization maximum periods are unchanged and limited to 12 months per the criteria.

    Policy Summary
    Payersierra health and life
    PolicyFcRn blockers (Rystiggo, Vyvgart, Vyvgart Hytrulo) coverage for gMG and CIDP
    Policy CodePolicy 2026D0111N
    Change TypeHCPCS code list updated
    Effective DateJan 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with medical records confirming antibody status, MGFA class, MG‑ADL score, and prior therapy history.
    SourceLink
    On This Page
    Coverage Criteria for FcRn Blocker TherapiesBilling and CodingProvider Actions, Prior Authorization, and DocumentationBackground and MechanismDefinitions and Responder CriteriaRevision History and Policy Changes
    gMG MuSK-positive indication (Rystiggo): Rystiggo is indicated for gMG in adult patients who are anti‑AChR or anti‑MuSK antibody positive
    CIDP indication (Vyvgart Hytrulo): For CIDP, documentation of definite or probable CIDP per EFNS/PNS criteria and demonstration of responder status in an initial open‑label phase (as in pivotal study) may mirror trial structure; randomized withdrawal showed longer time to deterioration for active drug
    Rozanolixizumab entry criteria noteRozanolixizumab pivotal trial used MG‑ADL ≥3 (with ≥3 non‑ocular points) as an enrollment threshold; primary endpoint assessed change at day 43
    Billing Rule

    Use updated HCPCS codes (J9256 added; C9305 removed)

    Request authorization using the policy's updated HCPCS code list; the policy added J9256 and removed C9305 in the latest annual edit.

    • Applicable HCPCS/J‑codes listed in policy include J9332, J9333, J9334, and J9256 per the coding section.
    Step Therapy

    Prior therapy requirements: document failed immunosuppressive and IVIG/plasmapheresis trials

    Document prior therapy trials as required before initiation: history of failure of at least two immunosuppressive agents over ≥12 months, or failure of ≥1 immunosuppressive plus ≥4 courses of plasmapheresis/IVIG over ≥12 months (criteria vary by agent and antibody status).

    • For AChR‑positive gMG (Vyvgart/Vyvgart Hytrulo/Rystiggo AChR): either ≥2 immunosuppressive agent failures over ≥12 months OR ≥1 immunosuppressive failure plus ≥4 plasmapheresis/IVIG courses over ≥12 months.
    • For MuSK‑positive Rystiggo patients: refer to the Rystiggo-specific requirement (failure of ≥1 immunosuppressive agent over ≥12 months where specified).
    • For CIDP (Vyvgart Hytrulo): document trial and failure (≥2 months) or intolerance/contraindication to corticosteroids and trial and failure (≥3 months) of IVIG/SCIG or documented intolerance/contraindication per CIDP criteria.
    Step Therapy

    Step edits and Medicare note: commercial step edits possible; Medicare has no NCD/LCD

    Be aware payer step edits and Medicare considerations: preferred‑therapy or step edits may be applied for commercial members, while preferred therapy criteria are not applicable for Medicare Advantage members and Medicare lacks an NCD/LCD for these agents.

    • Commercial plans may apply preferred‑therapy criteria or step edits consistent with policy logic.
    • Medicare: no NCD or LCD exists for these agents; preferred therapy criteria is not applicable for Medicare Advantage members but Part B coverage rules apply per benefit manuals.
    Documentation Required

    Required documentation to support PA: labs, scores, electrodiagnostics, and prior therapy history

    Include the following documentation with PA submission: chart notes, laboratory results (including antibody testing and serum IgG), baseline and follow‑up MG‑ADL scores, MGFA class documentation, electrodiagnostic testing for CIDP, and a detailed prior therapy history with dates and outcomes.

    • Positive serologic test results (anti‑AChR and/or anti‑MuSK where applicable) and serum IgG level if available.
    • MG‑ADL total score at baseline and documentation of any subsequent MG‑ADL changes.
    • MGFA clinical classification documented in chart notes.
    • Electrodiagnostic reports meeting EFNS/PNS criteria for CIDP when applicable.
    • Detailed prior therapy history: immunosuppressant names, durations, dates of IVIG/plasmapheresis courses, and reasons for discontinuation or intolerance.
    Note

    Suggested supporting clinical documentation: trial‑aligned inclusion data

    Provide suggested supporting clinical documentation that aligns with trial inclusion criteria: MGFA class II–IV (or II–IVa for rozanolixizumab), baseline MG‑ADL thresholds used in trials, stable concomitant MG therapy, and minimum serum IgG per trial enrollment.

    • Efgartigimod (Study 1) trial criteria: MGFA class II–IV, MG‑ADL ≥5, stable MG therapy, serum IgG ≥6 g/L.
    • Rozanolixizumab trial criteria: MGFA class II–IVa, MG‑ADL ≥3 with ≥3 non‑ocular points, stable MG therapy, serum IgG ≥5.5 g/L.
    • For CIDP, documentation per EFNS/PNS criteria and evidence of responder status in an initial open‑label phase may support requests.
    Denial Risk

    Triggers for possible denial: missing diagnosis, serology, MGFA class, MG‑ADL, or prior therapy evidence

    Requests lacking required diagnostic or prior‑therapy documentation may be denied. Common denial triggers include absence of confirmed diagnosis, missing positive serologic testing for the applicable antibody, no MGFA class II–IV documentation, MG‑ADL below policy threshold, or insufficient prior immunosuppressive/IVIG/plasmapheresis history.

    • Missing positive anti‑AChR or anti‑MuSK serology as required by the agent's criteria.
    • No documentation of MGFA clinical class II–IV at initiation.
    • MG‑ADL total score below policy minimum (e.g., <5 for most initiation criteria).
    • Insufficient evidence of required prior failures of immunosuppressants or IVIG/plasmapheresis as specified.
    Note

    Coverage limitations: FDA approval is informational; local and Medicare coverage may be absent

    Do not assume coverage solely because a product is FDA‑approved; the policy states FDA approval is informational only and Medicare lacks an NCD/LCD — absence of local coverage or member‑specific benefits may result in non‑coverage.

    • FDA approval does not guarantee coverage under this medical policy.
    • Medicare: no NCD/LCD exists for these agents; local coverage absence may affect reimbursement depending on plan benefits.
    Clinical effect measuredReduction in total IgG and specific autoantibody (e.g., anti‑AChR) levels observed in trials
    MG-ADL responder — trial‑specific framing
    Trial‑framed responder entryIn pivotal efgartigimod trials an MG‑ADL responder was defined as ≥2‑point reduction from cycle baseline sustained ≥4 weeks; rozanolixizumab trials enrolled patients with MG‑ADL ≥3 (≥3 non‑ocular points)
    Use for continuation decisionsContinuation criteria require documentation of the ≥2‑point MG‑ADL improvement from pretreatment baseline
    Enrollment thresholdsDifferent trials used baseline MG‑ADL thresholds (e.g., ≥5 for efgartigimod IV trial; ≥3 for rozanolixizumab) which inform policy applicability
    QMG responder — definition (≥3‑point reduction sustained ≥4 weeks)
    QMG responder definitionDefined as a ≥3‑point reduction in total QMG score from treatment‑cycle baseline sustained for ≥4 consecutive weeks
    QMG scale rangeQMG is a 13‑item scale with total score range 0–39; higher scores indicate greater weakness
    Use in trialsQMG responder status was a secondary endpoint in efgartigimod trials and used to assess muscle weakness improvement